• Skip to primary navigation
  • Skip to content
  • Skip to footer
Genelex Logo

Genelex

Pharmacogenetics Makes Precision Medicine Possible

  • Patients
    • Conditions
    • Affected Drugs
    • What is PGx?
    • Resources
    • FAQs
    • Patient Stories
  • Providers
    • Resources
    • Order Testing Supplies
  • Test Menu
  • Clinical Trials
  • About
    • Lab Accreditations
    • Genelex Team
    • News
    • Contact Us
  • Log In

ADE Risk and Study Concerns Halt FDA’s Xarelto Expansion

Home / News / ADE Risk and Study Concerns Halt FDA’s Xarelto Expansion

Genelex Blog

ADE Risk and Study Concerns Halt FDA's Xarelto Expansion

Last week an FDA advisory panel decided six-to-four against expanding the use of the prescription anticoagulant Xarelto (rivaroxaban). The drug's manufacturer, Johnson & Johnson, was hoping to gain the FDA's approval for Xarelto's use in treating acute coronary syndrome, a potentially life-threatening condition where a clot reduces blood flow to the heart. The syndrome is commonly treated through the use aspirin or Plavix, another anticoagulant drug similar to Xarelto.

Even though preliminary data suggests that Xarelto could be effective, doubts about the 15,500-patient study's data integrity and possible drug-drug interactions between Xarelto and Plavix concerned the panel members. While the panel acknowledged that Xarelto would be effective at treating the syndrome, they were unconvinced that the potential benefits outweighed the increased risk of bleeding events or other adverse drug effects.

The FDA will take the advisory panel's decision into account and release their final decision by June 29th. It is expected that they will follow the panel's opinions.

This decision does not affect Xarelto's use in treating previously approved conditions such as atrial fibrillation.

Sources: NYTimes, USNews, BusinessWeek

Genelex Resources

Affected Conditions
Affected Drugs
Info for Providers
Frequently Asked Questions
Contact Genelex
Join Our Mailing List
ORDER A TEST

Take a Risk Assessment

Simply enter the medications you’re currently on or plan to take. Click “Get Results” to see if your regimen puts you at risk for an adverse drug reaction.

YOUR GENELEX RISK ASSESSMENT RESULTS:

Reader Interactions

Footer

CONTACT US

(800) 837-8362
info@genelex.com

3101 Western Ave.
Suite 100
Seattle, WA 98121

HELPFUL INFORMATION

What is PGx?
Test Menu
Conditions
Affected Drugs
Resources
FAQs

ABOUT GENELEX

Blog
News
Genelex Team
Lab Accreditations
Testimonials

  • Facebook
  • LinkedIn
  • RSS
  • Twitter
  • YouTube

KEEP IN TOUCH

Stay in the loop with news and updates from Genelex and be among the first to know when new tests become available.

© GENELEX 2019 ・ PRIVACY POLICY ・ REFERENCES ・ CAP LAB 4344001 ・CLIA 50D0980559 ・NYDOH PFI 8201